Getting vaccinated against shingles (when offered to adults) could reduce the relative risk of developing major cognitive decline by 20%, thereby contributing to the preservation of brain longevity.

noli's read

The creator draws on a large-scale study published in the journal Nature (2025) by Pascal Geldsetzer's team at Stanford University. This research uses an innovative quasi-experimental model (regression discontinuity) based on birth dates in Wales, offering a level of evidence significantly superior to conventional observational studies. The analysis confirms a 20% reduction in the relative risk (approximately 3.5% in absolute value) of developing major cognitive decline over seven years. Nevertheless, as the creator points out, this protective benefit proved to be almost exclusively pronounced in women. It must also be specified that these data concern the older generation of shingles vaccine (Zostavax), now replaced by a more recent formula in many countries. Although preliminary observations regarding the new formula are encouraging for mental vitality, direct clinical validations remain necessary to establish it as a routine recommendation.

the sources

No named source held this one up — that absence is part of the verdict.